14811 When to Stop? Elagolix Continuation Beyond Maximum Duration Cutoffs and Uptake of Treatments Post-Elagolix in Patients with Endometriosis

RE Akerman, LA Humphries, PR Movilla, HR Haber, SN Morris
2025 · doi:10.1016/j.jmig.2025.09.319 · W7093086091
OA: closed CC0
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex
⚙ AI-generated summary by qwen3.7-flash, 2026-09-26 ⓘ

This paper evaluates the timing for discontinuing elagolix beyond maximum duration cutoffs and assesses the subsequent uptake of alternative treatments in patients with endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2025) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

openalex
last seen: 2026-05-11T04:29:15.117232+00:00
unpaywall
last seen: 2026-10-16T06:24:35.758740+00:00
License: CC0 · commercial use OK